Trial Results

October 14, 2019

Trial Results: With E1912, there is a new standard of care for the initial treatment of patients with chronic lymphocytic leukemia

The combination of ibrutinib plus rituximab was superior to standard treatment for CLL patients age 70 and younger.
February 12, 2020
crowd of women

Trial Results: New TAILORx data shows chemotherapy benefit for women at high risk of breast cancer recurrence

The TAILORx trial answers questions about when to use chemotherapy to treat the most common type of breast cancer.
June 6, 2020
Oropharynx image

Trial Results: ECOG-ACRIN plans to conduct a randomized phase 3 trial aimed at sparing people with oropharynx cancer unnecessary side effects from treatment, based on the recent results of phase 2 study E3311

This study showed that surgery followed by low-dose radiation alone led to very good outcomes, similar to surgery with standard-dose radiation, preserving patients’ throat function and potentially sparing them unnecessary side effects.
October 2, 2020
Woman holding cloud on string in place of head

Trial Results: For women with breast cancer in the TAILORx trial, cognitive decline from chemo was early and abrupt but did not get worse over time. Cognition also declined in the group on hormone therapy alone.

Cognitive loss—or ‘brain fog’—involves memory problems, a lack of mental clarity, and difficulty keeping one’s focus. Cancer-related brain fog is common during treatment. This study dispels the idea that it is only from chemotherapy.